ATE223229T1 - Zusammensetzungen aus konjugaten des stabilen, aktiven, menschlichen ob proteins mit der fc kette von immunoglobulinen und damit zusammenhängende verfahren - Google Patents

Zusammensetzungen aus konjugaten des stabilen, aktiven, menschlichen ob proteins mit der fc kette von immunoglobulinen und damit zusammenhängende verfahren

Info

Publication number
ATE223229T1
ATE223229T1 AT98918399T AT98918399T ATE223229T1 AT E223229 T1 ATE223229 T1 AT E223229T1 AT 98918399 T AT98918399 T AT 98918399T AT 98918399 T AT98918399 T AT 98918399T AT E223229 T1 ATE223229 T1 AT E223229T1
Authority
AT
Austria
Prior art keywords
human
protein
immunoglobulins
conjugates
compositions
Prior art date
Application number
AT98918399T
Other languages
English (en)
Inventor
David N Brems
Donna L French
Margaret A Speed
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/059,467 external-priority patent/US20020019352A1/en
Application filed by Amgen Inc filed Critical Amgen Inc
Application granted granted Critical
Publication of ATE223229T1 publication Critical patent/ATE223229T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Obesity (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Emergency Medicine (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
AT98918399T 1997-04-17 1998-04-16 Zusammensetzungen aus konjugaten des stabilen, aktiven, menschlichen ob proteins mit der fc kette von immunoglobulinen und damit zusammenhängende verfahren ATE223229T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US84397197A 1997-04-17 1997-04-17
US09/059,467 US20020019352A1 (en) 1997-04-17 1998-04-14 Stable, active, human ob protein compositions and methods
PCT/US1998/007828 WO1998046257A1 (en) 1997-04-17 1998-04-16 Compositions comprising conjugates of stable, active, human ob protein with antibody fc chain and methods

Publications (1)

Publication Number Publication Date
ATE223229T1 true ATE223229T1 (de) 2002-09-15

Family

ID=26738785

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98918399T ATE223229T1 (de) 1997-04-17 1998-04-16 Zusammensetzungen aus konjugaten des stabilen, aktiven, menschlichen ob proteins mit der fc kette von immunoglobulinen und damit zusammenhängende verfahren

Country Status (12)

Country Link
EP (1) EP0977583B1 (de)
JP (1) JP4086908B2 (de)
CN (1) CN1202862C (de)
AT (1) ATE223229T1 (de)
AU (1) AU7132798A (de)
CA (1) CA2286098C (de)
DE (1) DE69807679T2 (de)
ES (1) ES2183351T3 (de)
HK (1) HK1023513A1 (de)
HU (1) HU226175B1 (de)
IL (1) IL132380A0 (de)
WO (1) WO1998046257A1 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030040467A1 (en) 1998-06-15 2003-02-27 Mary Ann Pelleymounter Ig/ob fusions and uses thereof.
ES2339846T3 (es) * 1995-11-22 2010-05-26 Amgen Inc. Metodo para aumentar la masa de tejido magro usando composiciones de proteina ob.
US6936439B2 (en) 1995-11-22 2005-08-30 Amgen Inc. OB fusion protein compositions and methods
PL219605B1 (pl) 1998-10-23 2015-06-30 Kirin Amgen Inc Dimeryczne mimetyki peptydów trombopoetynowych wiążące się z receptorem MP1 i wykazujące aktywność trombopoetyczną
US7488590B2 (en) 1998-10-23 2009-02-10 Amgen Inc. Modified peptides as therapeutic agents
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
EP1128840A1 (de) * 1998-10-27 2001-09-05 Eli Lilly And Company Verhinderung eines muskelmasseverlust mit liganden des leptinrezeptors
WO2001083525A2 (en) * 2000-05-03 2001-11-08 Amgen Inc. Modified peptides, comprising an fc domain, as therapeutic agents
US20020090646A1 (en) * 2000-05-03 2002-07-11 Amgen Inc. Calcitonin-related molecules
EP1392826A2 (de) * 2001-01-18 2004-03-03 MERCK PATENT GmbH Bifunktionelle fusionsproteine mit glukocerebrosidase-aktivität
WO2002079415A2 (en) 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reducing the immunogenicity of fusion proteins
JP4606161B2 (ja) 2002-05-21 2011-01-05 アムジエン・インコーポレーテツド 置換複素環式化合物および使用方法
EA011859B9 (ru) 2004-01-05 2013-07-30 Емд Лексиген Ресерч Сентер Корп. Соединения для адресной доставки препарата к ткани или органу-мишени
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
US8227408B2 (en) 2005-09-07 2012-07-24 Neurotez, Inc. Leptin as an anti-amyloidogenic biologic and methods for delaying the onset and reducing Alzheimer's disease-like pathology
US8716220B2 (en) 2005-09-07 2014-05-06 Nikolaos Tezapsidis Leptin compositions and methods for treating progressive cognitive function disorders resulting from accumulation of neurofibrillary tangles and amyloid beta
TWI564021B (zh) 2008-04-11 2017-01-01 Chugai Pharmaceutical Co Ltd Repeated binding of antigen to antigen binding molecules
CA2725143A1 (en) 2008-05-21 2009-11-26 Neurotez, Inc. Methods for treating progressive cognitive disorders related to neurofibrillary tangles
US8501686B2 (en) 2008-06-05 2013-08-06 University Of Michigan Method of treating fatty liver diseases and conditions in non-lipodystrophic subjects
CN102405230A (zh) 2009-04-22 2012-04-04 默克专利有限公司 具有修饰的FcRn结合位点的抗体融合蛋白
EP2647706B1 (de) * 2010-11-30 2023-05-17 Chugai Seiyaku Kabushiki Kaisha Antigenbindende moleküle zur wiederholten bindung an mehrere antigenmoleküle
JP6032818B2 (ja) 2011-02-25 2016-11-30 中外製薬株式会社 ＦｃγＲＩＩｂ特異的Ｆｃ抗体
EP2762493B1 (de) 2011-09-30 2021-06-09 Chugai Seiyaku Kabushiki Kaisha Antigenbindende moleküle zur förderung der zersetzung von antigenen mit mehreren biologischen aktivitäten
RU2650646C2 (ru) 2012-09-27 2018-04-16 Дзе Чилдрен'З Медикал Сентер Корпорейшн Соединения, предназначенные для лечения ожирения, и способы их применения
AU2014354831B2 (en) 2013-11-26 2017-10-26 The Children's Medical Center Corporation Compounds for the treatment of obesity and methods of use thereof
WO2015153933A1 (en) 2014-04-03 2015-10-08 The Children's Medical Center Corporation Hsp90 inhibitors for the treatment of obesity and methods of use thereof
TWI656133B (zh) 2014-12-19 2019-04-11 日商中外製藥股份有限公司 抗肌抑素之抗體、含變異Ｆｃ區域之多胜肽及使用方法
MY183415A (en) 2014-12-19 2021-02-18 Chugai Pharmaceutical Co Ltd Anti-c5 antibodies and methods of use
EP3253778A1 (de) 2015-02-05 2017-12-13 Chugai Seiyaku Kabushiki Kaisha Antikörper mit einer ionenkonzentrationsabhängigen antigenbindenden domäne, fc-region-varianten, il-8-bindende antikörper und verwendungen davon
US11359009B2 (en) 2015-12-25 2022-06-14 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
CA3026050A1 (en) 2016-08-05 2018-02-08 Chugai Seiyaku Kabushiki Kaisha Composition for prophylaxis or treatment of il-8 related diseases
MX2019002818A (es) 2016-09-12 2019-08-29 Aegerion Pharmaceuticals Inc Metodos para detectar anticuerpos neutralizantes anti-leptina.
EP3574010A4 (de) 2017-01-30 2020-12-16 Chugai Seiyaku Kabushiki Kaisha Anti-sclerostin-antikörper und verfahren zur verwendung

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5559208A (en) * 1995-01-31 1996-09-24 Eli Lilly And Company Anti-obesity proteins
GB9511935D0 (en) * 1995-06-13 1995-08-09 Smithkline Beecham Plc Novel compound
RU2178307C2 (ru) * 1995-12-27 2002-01-20 Джинентех Инк. Производные ов-протеина
JP4175668B2 (ja) * 1996-12-20 2008-11-05 アムジエン・インコーポレーテツド Ｏｂ融合タンパク質組成物および方法

Also Published As

Publication number Publication date
CA2286098C (en) 2009-07-07
WO1998046257A1 (en) 1998-10-22
HU226175B1 (en) 2008-06-30
CN1274289A (zh) 2000-11-22
AU7132798A (en) 1998-11-11
HUP0002831A2 (hu) 2000-12-28
DE69807679D1 (de) 2002-10-10
JP4086908B2 (ja) 2008-05-14
CN1202862C (zh) 2005-05-25
IL132380A0 (en) 2001-03-19
DE69807679T2 (de) 2003-07-31
EP0977583A1 (de) 2000-02-09
HUP0002831A3 (en) 2005-11-28
ES2183351T3 (es) 2003-03-16
CA2286098A1 (en) 1998-10-22
HK1023513A1 (en) 2000-09-15
JP2002512612A (ja) 2002-04-23
WO1998046257A8 (en) 2000-01-27
EP0977583B1 (de) 2002-09-04

Similar Documents

Publication Publication Date Title
ATE223229T1 (de) Zusammensetzungen aus konjugaten des stabilen, aktiven, menschlichen ob proteins mit der fc kette von immunoglobulinen und damit zusammenhängende verfahren
NZ330897A (en) Human trk receptors and neurotropic factor inhibitors
DE69330643T2 (de) Monoklonaler antikörper, welcher spezifisch an vaskularisiertes tumorendothelium bindet und verwendungen davon
ES2196031T3 (es) Derivados peptidicos terapeutico.
CO4830493A1 (es) Anticuerpos contra cd40 humano
DE69637781D1 (de) Für den il-13 rezeptor spezifische chimäre proteine und ihre verwendungen
PL336306A1 (en) Proteinous fusions of tgf-beta ii type receptor with a constant immunoglobulin area
NZ512083A (en) Methods of increasing lean tissue mass using OB protein compositions
DE60025832D1 (de) Mehrere zytokin-antikörper komplexen
EP1200124A4 (de) Immunglobulin fusionsproteine
DE69915320D1 (de) Immunoglobulin-bindende proteine
DK0754229T3 (da) Afamin: et humant serum albumin-lignende protein
DE59608073D1 (de) Antikörper gegen ein, einen histidin-anteil aufweisendes fusionspolypeptid
EA200001252A1 (ru) КОМПОЗИЦИЯ РЕКОМБИНАНТНОГО ИНТЕРФЕРОНА-β-1A(IFN-β-1A) ЧЕЛОВЕКА
DE59509948D1 (de) Konjugat aus einem wirkstoff und einem nicht als körperfremd angesehenen, nativen protein
ATE293996T1 (de) Lage-spezifische markierung von disulfide- enthaltenden zielgerichteten vektoren
ES2114527T3 (es) Anticuerpos que reconocen especificamente la proteina de enlace de la somatotropina.
TH17783EX (th) ทอกซินลูกผสม

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0977583

Country of ref document: EP